Alkermes
ALKS
41.45
-0.21
-0.49%
Alkermes
US · ALKS
#1780 by market cap
Listed 1970
41.45
-0.21
-0.49%
Live - 5344 symbols - heartbeat 278s ago
· 2026-10-08 07:21
Pre-market
40.96
-1.17%
After-hours
41.45
0.00%
- Market cap
- 6.95B
- P/E (TTM)i
- 109.07
- P/Bi
- 3.84
- EPSi
- 1.43
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on ALKS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.43, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -5.25% YoY
Margins
- Gross margin
- 86.69%
- Operating margin
- 17.21%
- Net margin
- 16.37%
Key ratios & quality
- Altman Z-Scorei
- 7.43
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 1.17B | 1.04B | 1.17B | 1.11B | 1.66B | 1.56B | 1.48B |
| Gross profit | 917.85M | 990.56M | 860.44M | 976.43M | 893.73M | 1.41B | 1.31B | 1.28B |
| Selling & admin expenses | 526.41M | 599.45M | 538.83M | 549.61M | 590.75M | 689.75M | 645.24M | 701.52M |
| Research & development | 425.41M | 512.83M | 394.59M | 290.92M | 272.70M | 270.81M | 245.33M | 323.96M |
| Operating profit | -99.13M | -162.08M | -112.43M | 97.75M | -6.09M | 414.12M | 420.64M | 253.96M |
| Pretax profit | -126.97M | -197.06M | -96.54M | 87.73M | -31.13M | 421.52M | 443.75M | 291.45M |
| Tax | 12.34M | -436.00K | 14.32M | 11.33M | 2.02M | -97.64M | 71.61M | 49.79M |
| Net profit | -139.31M | -196.62M | -110.86M | -48.17M | -158.27M | 355.76M | 367.07M | 241.66M |
| Basic EPS | -1 | -1 | -1 | 0 | -1 | 2 | 2 | 1 |
| Diluted EPS | -0.90 | -1.25 | -0.70 | -0.30 | -0.97 | 2.10 | 2.17 | 1.43 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 306.51M | 390.66M | 394.19M | 384.55M | 392.91M | 496.01M |
| Gross profit | 257.31M | 341.20M | 342.59M | 338.34M | 331.33M | 397.90M |
| Selling & admin expenses | 171.70M | 170.85M | 171.77M | 187.20M | 264.59M | 217.63M |
| Research & development | 71.82M | 77.37M | 81.74M | 93.04M | 103.35M | 112.92M |
| Operating profit | 13.79M | 92.98M | 89.08M | 58.10M | -48.28M | 44.77M |
| Pretax profit | 25.49M | 104.84M | 100.75M | 60.38M | -61.93M | -1.88M |
| Tax | 3.03M | 17.74M | 17.98M | 11.04M | 4.55M | -2.38M |
| Net profit | 22.46M | 87.10M | 82.76M | 49.34M | -66.48M | 501.00K |
| Basic EPS | 0 | 1 | 1 | 0 | 0 | 0 |
| Diluted EPS | 0.13 | 0.52 | 0.49 | 0.29 | -0.40 | 0.00 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 983.25M | 961.97M | 1.11B | 1.06B | 1.13B | 1.49B | 1.42B | 1.93B |
| Cash & ST investments | 539.30M | 534.98M | 635.03M | 536.31M | 608.47M | 773.49M | 751.67M | 588.22M |
| Inventory | 90.20M | 101.80M | 125.74M | 150.34M | 181.42M | 186.41M | 182.89M | 196.63M |
| Total assets | 1.83B | 1.81B | 1.95B | 2.02B | 1.96B | 2.14B | 2.06B | 2.49B |
| Total current liabilities | 339.77M | 391.11M | 438.26M | 471.29M | 497.74M | 520.22M | 465.20M | 543.44M |
| Short-term debt | 2.84M | 11.31M | 18.58M | 19.24M | 12.88M | 8.75M | 6.17M | 6.75M |
| Long-term debt | 276.47M | 274.30M | 272.12M | 292.80M | 290.27M | 287.73M | -- | -- |
| Total liabilities | 653,722,000.00 | 719,961,000.00 | 882,748,000.00 | 911,900,000.00 | 920,225,000.00 | 933,537,000.00 | 590,590,000.00 | 667,698,000.00 |
| Total equity | 1.17B | 1.09B | 1.07B | 1.11B | 1.04B | 1.20B | 1.46B | 1.82B |
| Retained earnings | -1.19B | -1.38B | -1.49B | -1.54B | -1.70B | -1.34B | -976.46M | -734.79M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.48B | 1.64B | 1.74B | 1.93B | 1.36B | 1.52B |
| Cash & ST investments | 884.02M | 1.02B | 1.11B | 588.22M | 511.86M | 656.58M |
| Inventory | 183.44M | 191.92M | 191.00M | 196.63M | 336.70M | 298.96M |
| Total assets | 2.08B | 2.25B | 2.33B | 2.49B | 4.26B | 4.39B |
| Total current liabilities | 443.73M | 505.96M | 474.36M | 543.44M | 599.50M | 662.09M |
| Short-term debt | 6.29M | 6.46M | 6.63M | 6.75M | 34.08M | 33.98M |
| Long-term debt | -- | -- | -- | -- | 1.48B | 1.48B |
| Total liabilities | 570,394,000.00 | 628,225,000.00 | 596,080,000.00 | 667,698,000.00 | 2,506,545,000.00 | 2,584,575,000.00 |
| Total equity | 1.51B | 1.62B | 1.73B | 1.82B | 1.75B | 1.81B |
| Retained earnings | -953.99M | -866.90M | -784.14M | -734.79M | -801.27M | -800.77M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 99.28M | 72.08M | 82.84M | 101.72M | 21.04M | 401.35M | 439.12M | 520.75M |
| Depreciation & amortization | 103.66M | 80.41M | 81.85M | 78.65M | 77.86M | 74.93M | 28.53M | 27.17M |
| Free cash flow | 29.85M | -18.87M | 40.62M | 72.70M | -17.21M | 353.31M | 405.64M | 480.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -200.28M | 0 |
| Ending cash balance | 266.76M | 203.77M | 272.96M | 337.54M | 292.47M | 457.47M | 291.15M | 1.12B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 98.81M | 150.20M | 101.67M | 170.07M | -165.74M | 145.18M |
| Depreciation & amortization | 7.42M | 7.82M | 8.08M | 3.85M | 19.43M | 30.28M |
| Free cash flow | 88.70M | 137.19M | 84.36M | 170.09M | -169.83M | 137.04M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | -27.70M | 0 |
| Ending cash balance | 399.81M | 521.20M | 616.45M | 1.12B | 351.55M | 511.53M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -11.74 | -17.43 | -10.30 | -4.42 | -14.68 | 31.67 | 27.52 | 14.72 |
| ROA %i | -7.69 | -10.83 | -5.90 | -2.42 | -7.94 | 17.35 | 17.51 | 10.64 |
| ROIC %i | -9.19 | -13.94 | -7.68 | -2.78 | -10.31 | 23.17 | 22.49 | 12.50 |
| 5-year avg ROE %i | -12.11 | -15.11 | -13.82 | -11.40 | -11.71 | -3.03 | 5.96 | 10.96 |
| EBIT margin %i | -10.19 | -15.67 | -8.46 | -2.39 | -13.88 | 26.73 | 29.94 | 20.58 |
| FCF / sales %i | 2.73 | -- | 3.91 | 6.19 | -- | 21.24 | 26.04 | 32.55 |
| Current ratioi | 2.89 | 2.46 | 2.53 | 2.25 | 2.27 | 2.86 | 3.04 | 3.55 |
| Quick ratioi | 2.47 | 2.05 | 2.11 | 1.83 | 1.82 | 2.13 | 2.45 | 1.70 |
| Debt / assetsi | 15.30 | 16.12 | 21.04 | 20.56 | 19.32 | 17.42 | 3.67 | 2.81 |
| LT debt / equityi | 23.60 | 25.76 | 36.70 | 35.68 | 35.12 | 30.22 | 4.74 | 3.48 |
| Interest coveragei | -7.22 | -13.49 | -10.15 | -2.50 | -11.83 | 19.30 | 20.65 | 24.74 |
| Revenue CAGR (3Y) %i | 20.31 | 16.23 | 4.76 | 2.36 | -1.71 | 16.99 | 9.89 | 9.90 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | 34.54 | -- | 105.65 | 77.37 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 25.50 | 23.96 | 22.40 | 14.72 | 9.36 | 3.85 |
| ROA %i | 16.77 | 15.63 | 15.11 | 10.64 | 4.82 | 1.99 |
| ROIC %i | 20.58 | 19.14 | 17.62 | 12.50 | 5.89 | 3.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 29.00 | 27.97 | 26.66 | 20.58 | 15.18 | 9.38 |
| FCF / sales %i | 31.81 | 31.88 | 32.27 | 32.55 | 14.20 | 13.29 |
| Current ratioi | 3.33 | 3.23 | 3.67 | 3.55 | 2.27 | 2.30 |
| Quick ratioi | 2.72 | 2.71 | 3.09 | 1.70 | 1.53 | 1.68 |
| Debt / assetsi | 3.56 | 3.23 | 3.07 | 2.81 | 37.14 | 35.80 |
| LT debt / equityi | 4.49 | 4.08 | 3.75 | 3.48 | 88.36 | 85.07 |
| Interest coveragei | 26.44 | 39.55 | 87.27 | 24.74 | 7.15 | 2.65 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing, manufacturing and commercializing medicines designed to help people living with complex100.00%
Quote time 2026-10-08 07:21:04 · For reference only, not investment advice and not tailored to your situation.